Testing trametinib and steroid plus chemo for relapsed blood cancers
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This early-phase trial tests whether adding trametinib and dexamethasone to standard chemotherapy can improve outcomes for children whose blood cancer has come back or did not respond. Because it is a Phase 1/2 study, the main goal is to see safety and learn the best way to treat your specific cancer type.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child must be age 1 to 18 (with an extra age limit for first diagnosis), and at least a minimum body weight: 7 kg if under 6 years, or 10 kg if 6+ years
- Your child must be well enough to take part (based on performance/play score being at least 50%)
- Before enrollment, the cancer must be tested with molecular testing and flow-cytometry to describe the relapse/refractory disease
- The cancer must have a specific “RAS pathway” change (for example KRAS, NRAS, HRAS, MAP2K1, PTPN11, NF1 loss, among others)
- Heart, kidney, and liver tests must be within allowable ranges, and the heart rhythm (QT interval) must not be too prolonged
- Your child must not have had trametinib before, must avoid certain medicines during the study, and must meet timing rules after prior treatments
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1/2 trial tests a combination of medicines (dasatinib, venetoclax, dexamethasone, cyclophosphamide, and cytarabine) in children and teens whose blood cancer has come back or did not respond to treatment. It aims to see whether this approach can control the cancer while checking what doses are safe.
This Phase 1/2 study tests a multi-drug combination (ruxolitinib, venetoclax, dexamethasone, plus chemotherapy) for children whose blood cancer has come back or did not respond. It aims to reduce the cancer by targeting specific genetic changes and may offer a new option when standard treatments have not worked.
This trial tests a combination of three drugs (capivasertib, venetoclax, and dexamethasone) for children and young adults whose blood cancer has come back or not responded to treatment. The goal is to see if this combination can help shrink or control the cancer.
This trial studies a treatment approach for children and teens newly diagnosed with lymphoblastic lymphoma. It may help doctors choose therapies based on genetic risk information from lab testing done on tumor samples.
This trial tests a combination of two drugs for children and teens with Langerhans cell histiocytosis (LCH) that has not responded to standard treatments or has come back after treatment. The goal is to see if the drugs can shrink lesions and improve symptoms.
This Phase 2 trial studies whether a targeted medicine that blocks MEK can work better than chemotherapy for certain slow-growing brain tumors in children. You may qualify if your tumor has specific genetic features and has not already been treated with non-surgery therapies.
Hear when a new Acute Lymphoblastic Leukemia, in Relapse trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.